BR112022012057A2 - Novos métodos de entrega celular - Google Patents

Novos métodos de entrega celular

Info

Publication number
BR112022012057A2
BR112022012057A2 BR112022012057A BR112022012057A BR112022012057A2 BR 112022012057 A2 BR112022012057 A2 BR 112022012057A2 BR 112022012057 A BR112022012057 A BR 112022012057A BR 112022012057 A BR112022012057 A BR 112022012057A BR 112022012057 A2 BR112022012057 A2 BR 112022012057A2
Authority
BR
Brazil
Prior art keywords
delivery methods
new cell
cell delivery
seq
rrsrtaragrpgrnssrpsapr
Prior art date
Application number
BR112022012057A
Other languages
English (en)
Portuguese (pt)
Inventor
Stone Shane
Hall Clinton
Stirnweiss Anja
Cunningham Paula
Original Assignee
Pyc Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019904882A external-priority patent/AU2019904882A0/en
Application filed by Pyc Therapeutics Ltd filed Critical Pyc Therapeutics Ltd
Publication of BR112022012057A2 publication Critical patent/BR112022012057A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
BR112022012057A 2019-12-20 2020-12-18 Novos métodos de entrega celular BR112022012057A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2019904882A AU2019904882A0 (en) 2019-12-20 Novel Cellular Delivery Methods
PCT/AU2020/051397 WO2021119756A1 (en) 2019-12-20 2020-12-18 Novel cellular delivery methods

Publications (1)

Publication Number Publication Date
BR112022012057A2 true BR112022012057A2 (pt) 2022-08-30

Family

ID=76476454

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022012057A BR112022012057A2 (pt) 2019-12-20 2020-12-18 Novos métodos de entrega celular

Country Status (10)

Country Link
US (1) US12698307B2 (enExample)
EP (1) EP4077354A4 (enExample)
JP (1) JP7684971B2 (enExample)
KR (1) KR20220117914A (enExample)
CN (1) CN115190884B (enExample)
AU (1) AU2020406670B2 (enExample)
BR (1) BR112022012057A2 (enExample)
CA (1) CA3161901A1 (enExample)
IL (1) IL294050A (enExample)
WO (1) WO2021119756A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019165183A1 (en) 2018-02-22 2019-08-29 Entrada Therapeutics, Inc. Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
CA3161901A1 (en) 2019-12-20 2021-06-24 Shane Stone Novel cellular delivery methods
US12338437B2 (en) 2020-05-11 2025-06-24 Stoke Therapeutics, Inc. OPA1 antisense oligomers for treatment of conditions and diseases
EP4469576A4 (en) * 2022-01-27 2026-04-15 Univ Alberta Antisense therapeutic products conjugate to pre-MIARN splicing modulating peptides for the treatment of diseases
WO2024073042A1 (en) * 2022-09-30 2024-04-04 Entrada Therapeutics, Inc. Ocular delivery of therapeutic agents
WO2024254639A1 (en) * 2023-06-16 2024-12-19 PYC Therapeutics Limited Compositions and methods for treatment of kidney disease
WO2025238644A1 (en) * 2024-05-16 2025-11-20 Skip Therapeutics Ltd. Compositions and methods for treating retinal diseases
WO2025240993A1 (en) * 2024-05-24 2025-11-27 PYC Therapeutics Limited Improved cell penetrating peptides and related compositions and methods

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566330B1 (en) 1996-10-22 2003-05-20 Medical University Of South Carolina Foundation Research Development Positively charged non-natural amino acids, methods of making and using thereof in peptides
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
JP2004520803A (ja) 2000-04-21 2004-07-15 コリクサ コーポレイション 尋常性挫瘡の治療および診断のための組成物および方法
US7214786B2 (en) * 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US20060107345A1 (en) * 2003-09-30 2006-05-18 Nickolai Alexandrov Sequence-determined DNA fragments and corresponding polypeptides encoded thereby
US20160340683A1 (en) 2007-06-07 2016-11-24 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Agriculture And Agr Nanocarrier based plant transfection and transduction
NZ704191A (en) * 2010-06-14 2016-05-27 Hoffmann La Roche Cell-penetrating peptides and uses therof
KR102046830B1 (ko) * 2011-05-13 2019-11-20 코벤하븐스 유니버시테트 허혈성 뇌 손상에 대한 효과적인 신경보호제이며 통증의 치료를 위한 psd-95의 고-친화성, 이량체 저해제
AU2013316679B2 (en) 2012-09-13 2017-12-14 Les Hopitaux Universitaires De Geneve Cell penetrating peptides
US10316061B2 (en) * 2014-10-02 2019-06-11 Temple University Of The Commonwealth System Of Higher Education Synthesis of cell penetrating peptides for drug delivery and stem cell applications
EP3630131B1 (en) * 2017-06-02 2022-08-31 Arizona Board of Regents on behalf of Arizona State University A method to create personalized canine cancer vaccines
US20210087238A1 (en) * 2017-07-28 2021-03-25 Phylogica Limited Cell penetrating peptides and related compositions and methods
CA3161901A1 (en) 2019-12-20 2021-06-24 Shane Stone Novel cellular delivery methods
WO2025043278A1 (en) 2023-08-25 2025-03-06 PYC Therapeutics Limited Gene-mediated conditions

Also Published As

Publication number Publication date
CN115190884A (zh) 2022-10-14
JP2023511501A (ja) 2023-03-20
US20230048338A1 (en) 2023-02-16
JP7684971B2 (ja) 2025-05-28
EP4077354A1 (en) 2022-10-26
AU2020406670A1 (en) 2022-07-14
IL294050A (en) 2022-08-01
WO2021119756A1 (en) 2021-06-24
CA3161901A1 (en) 2021-06-24
KR20220117914A (ko) 2022-08-24
US12698307B2 (en) 2026-08-04
AU2020406670B2 (en) 2026-03-05
CN115190884B (zh) 2026-01-13
EP4077354A4 (en) 2024-01-24

Similar Documents

Publication Publication Date Title
PE20190335A1 (es) Receptores de celulas t
PE20210376A1 (es) Peptidos y combinacion de peptidos de origen no canonico para el uso en la inmunoterapia contra diferentes tipos de cancer
BR112021021912A2 (pt) Nova nuclease omni-50 crispr
EP3712165A3 (en) Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
MX2020008902A (es) Analogos de compstatina y sus usos medicos.
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
ES2531142T3 (es) Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden
IN2014CN02050A (enExample)
EA201000327A1 (ru) Белок
AU2018280528A8 (en) Method for improving transformation efficiency of plant and method for transforming plant
EP3939606A3 (en) Improved methods and compounds for eliminating immune responses to therapeutic agents
ATE462000T1 (de) Verfahren zur herstellung von l-arginin, l- ornithin oder l-citrullin
NZ600731A (en) Oxyntomodulin peptide analogue
MX2022002433A (es) Análogos de compstatina y sus usos médicos.
WO2020044296A3 (en) Recombinant lectin variants
MY206219A (en) Klk5 inhibitory peptide
NZ609916A (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
MX2025000087A (es) Edulcorantes proteicos
MX2021001507A (es) Farmaco de diagnostico y metodo de diagnostico para la enfermedad de alzheimer.
MX2022001211A (es) Moléculas del complejo mayor de histocompatibilidad (mhc) de clase ii y métodos para su uso.
MX2017010259A (es) Proteina resistente a herbicidas, gen codificante y uso de los mismos.
PH12017502323A1 (en) Novel xylanase
MX2010005816A (es) Epítopos de péptido de stat3.
EP4282960A3 (en) Modified lipase and use thereof
NZ589365A (en) Peptidyl diacylglycerides